ABEO
Price
$5.63
Change
+$0.03 (+0.54%)
Updated
May 13 closing price
Capitalization
274.74M
96 days until earnings call
BCRX
Price
$10.06
Change
-$0.28 (-2.71%)
Updated
May 13 closing price
Capitalization
2.11B
78 days until earnings call
Ad is loading...

ABEO vs BCRX

Header iconABEO vs BCRX Comparison
Open Charts ABEO vs BCRXBanner chart's image
Abeona Therapeutics
Price$5.63
Change+$0.03 (+0.54%)
Volume$2.08M
Capitalization274.74M
BioCryst Pharmaceuticals
Price$10.06
Change-$0.28 (-2.71%)
Volume$6.12M
Capitalization2.11B
ABEO vs BCRX Comparison Chart
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. BCRX commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a StrongBuy and BCRX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (ABEO: $5.63 vs. BCRX: $10.06)
Brand notoriety: ABEO: Not notable vs. BCRX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 102% vs. BCRX: 133%
Market capitalization -- ABEO: $274.74M vs. BCRX: $2.11B
ABEO [@Biotechnology] is valued at $274.74M. BCRX’s [@Biotechnology] market capitalization is $2.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $295.2B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • BCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, BCRX is a better buy in the long-term than ABEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 6 TA indicator(s) are bullish while BCRX’s TA Score has 6 bullish TA indicator(s).

  • ABEO’s TA Score: 6 bullish, 4 bearish.
  • BCRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ABEO and BCRX are a good buy in the short-term.

Price Growth

ABEO (@Biotechnology) experienced а -2.17% price change this week, while BCRX (@Biotechnology) price change was -2.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +9.41%, and the average quarterly price growth was -8.48%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

BCRX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($2.11B) has a higher market cap than ABEO($275M). BCRX YTD gains are higher at: 33.777 vs. ABEO (1.077). BCRX has higher annual earnings (EBITDA): 47.6M vs. ABEO (-64.95M). BCRX has more cash in the bank: 295M vs. ABEO (110M). ABEO has less debt than BCRX: ABEO (23.1M) vs BCRX (795M). BCRX has higher revenues than ABEO: BCRX (503M) vs ABEO (0).
ABEOBCRXABEO / BCRX
Capitalization275M2.11B13%
EBITDA-64.95M47.6M-136%
Gain YTD1.07733.7773%
P/E RatioN/AN/A-
Revenue0503M-
Total Cash110M295M37%
Total Debt23.1M795M3%
FUNDAMENTALS RATINGS
ABEO vs BCRX: Fundamental Ratings
ABEO
BCRX
OUTLOOK RATING
1..100
7013
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4335
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (31) in the Biotechnology industry is in the same range as ABEO (60) in the Pharmaceuticals Generic industry. This means that BCRX’s stock grew similarly to ABEO’s over the last 12 months.

BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for ABEO (100) in the Pharmaceuticals Generic industry. This means that BCRX’s stock grew somewhat faster than ABEO’s over the last 12 months.

ABEO's SMR Rating (98) in the Pharmaceuticals Generic industry is in the same range as BCRX (100) in the Biotechnology industry. This means that ABEO’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (35) in the Biotechnology industry is in the same range as ABEO (43) in the Pharmaceuticals Generic industry. This means that BCRX’s stock grew similarly to ABEO’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that BCRX’s stock grew similarly to ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOBCRX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
87%
View a ticker or compare two or three
Ad is loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VWIAX60.90N/A
N/A
Vanguard Wellesley® Income Admiral™
JHTRX19.04N/A
N/A
JPMorgan Hedged Equity 3 R6
HAMVX25.90N/A
N/A
Harbor Mid Cap Value Instl
SJVAX28.65N/A
N/A
Steward Large Cap Value A
MIFOX29.44N/A
N/A
Marsico Focus Institutional

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ELVN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.54%
ELVN - ABEO
46%
Loosely correlated
+5.37%
ERAS - ABEO
45%
Loosely correlated
-4.32%
RGLS - ABEO
44%
Loosely correlated
-0.38%
APGE - ABEO
44%
Loosely correlated
+0.40%
CRNX - ABEO
44%
Loosely correlated
-7.11%
More